Interestingly, we have shown in our study that HMGB1, HMGB2 and their EOC-HMGB-interactome partners MIEN1 and NOP53 are involved in the response to carboplatin, or drugs nowadays used in ovarian cancer treatment, such as bevacizumab, olaparib and paclitaxel. Here, MIEN1 is linked to ovarian cancer.